Teva wins EU nod for Ajovy migraine prophylactic
Teva (NYSE:TEVA) said yesterday that it won EC Marketing Authorization for its Ajovy pre-filled syringe injection meant to serve as a prophylaxis for migraines in adults who experience at least four migraine days per month.
The Israel-based company said that Ajovy is a humanized monoclonal antibody that binds to the calcitonin gene-related peptide ligand and blocks its binding to the receptor.
Read the whole story on our sister site, Drug Delivery Business News
Source: Mass Device - Category: Medical Devices Authors: Fink Densford Tags: Neurological Pharmaceuticals Regulatory/Compliance Teva Pharmaceuticals Source Type: news
More News: Brain | Genetics | Headache | Israel Health | Marketing | Medical Devices | Middle East Health | Migraine | Neurology